Insilico Medicine

Hong Kong’s Insilico Medicine bags new investment led by Aramco-backed Prosperity7 Ventures

Insilico Medicine, a Hong Kong-based clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced Wednesday that it has completed a second closing of its Series D round, led by Prosperity7 Ventures, the diversified growth fund of Aramco Ventures, bringing the total Series D financing to $95 million.

Insilico Medicine closes $255M Series C led by Warburg Pincus to further develop AI and drug discovery

Proceeds from the funding will be used to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities, the company added.